Project Grant K99CA300504
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $1,098,920 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on August 13, 2025, with a completion date of April 30, 2030. The grant supports fundamental research to understand the transcriptional and epigenetic mechanisms controlling CD8+ tumor-infiltrating lymphocytes (TILs), with specific focus on the transcription...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $174,949 under the Cancer Research Manpower program (CFDA 93.398) for the period of July 1, 2026, through June 30, 2029. The award funds research investigating the role of tumor cell-intrinsic stimulator of interferon genes (STING) signaling in the spontaneous and therapeutic induction of tertiary lymphoid structures (TLSs) within melanoma....
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. This award supports exploratory research into the role of antisense ribonucleic acids (asRNAs) in melanoma development and transformation. The project will deliver scientific research and analysis focused on...
- Federal Grant Award Summary The National Cancer Institute, under its Cancer Treatment Research program (CFDA 93.395), awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 effective June 1, 2026, with completion targeted for May 31, 2028. This award supports research into fragment-based targeting of epithelial-to-mesenchymal transition (EMT)-mediated resistance in epidermal growth factor receptor (EGFR)-mutant lung cancer. The project leverages...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a Project Grant totaling $257,472 (awarded September 6, 2025; completion date March 6, 2029) under the Cancer Research Manpower program (CFDA 93.398) to support research dissecting the impact of genomic variants on T cell anti-tumor activity. The funded research addresses the critical challenge that while some patients with melanomas and leukemias respond durably to T...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $157,248 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) to support biomedical research training and career development in cancer research. The award, effective September 1, 2025, through August 31, 2028, funds investigator-initiated research focused on understanding the oncogenic roles of alarmins and monocytes in triple...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $687,593 under the Cancer Biology Research program (CFDA 93.396) on May 12, 2026, with completion anticipated by April 30, 2031. This grant funds fundamental research into cysteine acquisition and utilization in lung adenocarcinoma, challenging the current understanding of how tumor cells obtain cysteine from their microenvironment....
- Federal Project Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $1.43 million Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), effective September 8, 2025, through May 31, 2030. The award supports the development and validation of ultrasensitive, non-invasive liquid biopsy tests for head and neck squamous cell carcinoma (HNSCC)...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Miami's Office of Research Administration - School of Medicine Division a Project Grant of $110,228 under the Cancer Research Manpower program (CFDA 93.398), effective December 1, 2026 through May 31, 2030. This award supports the development and comparative analysis of Chimeric Ligand-Presenting (CLIP) T cells as a novel cellular immunotherapy for Extranodal NK/T-Cell Lymphoma (ENKTL), a rare and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $248,999 to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. under the Cancer Biology Research program (CFDA 93.396) on June 1, 2026, for a three-year project period concluding May 31, 2029. This Project Grant supports fundamental research investigating the role of oral microbiota in metastatic brain tumors, a critical clinical challenge associated with high morbidity and mortality. The research builds on...
The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. $119,597 under the Cancer Research Manpower program (CFDA 93.398) for a project grant focused on engineering antigen-specific tumor-infiltrating lymphocytes (TIL) for adoptive cell therapy of head and neck squamous cell carcinoma (HNSCC). The grant, awarded July 3, 2026, with completion targeted for June 30, 2028, supports biomedical training and research development for Dr. Hall to advance his career as an independent investigator in cancer immunotherapy. The research will generate novel cellular therapy products through systematic investigation of tumor-reactive TIL biology and engineering strategies to overcome immunotherapeutic resistance mechanisms. Under this award, the awardee will deliver research services and training that includes functional evaluation of tumor-reactive HNSCC TIL using advanced molecular and immunologic techniques such as next-generation sequencing, immunopeptidomics, and spatial transcriptomics; development of T cell engineering strategies utilizing CRISPR/Cas9 and T cell receptor (TCR) transgenic approaches; and validation of findings in murine HNSCC models. The project is designed to produce a comprehensive understanding of TIL biology in the therapeutic setting while generating engineered cellular therapy products to address mechanisms of immunotherapy resistance in HNSCC patients.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $119.6k | 7/9/26 |